HYPERTENSIVES AND MEDICAL MANAGEMENT: ARE THEY SILENT CONTRIBUTORS TO THE BURDEN OF LUNG DISEASE IN OUR SOCIETY
| Main Authors: | Sitalakshmi Ramadoss, Rajam Krishna Subramanian, Mahila Subramanian, Sai Kumar Pindigiri, Muthyala Pavan Kumar, Valarmathi Srinivasan |
|---|---|
| Format: | Article Journal |
| Bahasa: | eng |
| Terbitan: |
, 2018
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/4480479 |
Daftar Isi:
- Background and objectives: Hypertension is increasing globally with another 60% expected increase by 2025. In spite of advancing research and different classes of anti- hypertensive medications (anti-HT), not all of them can be branded safe. Pulmonary complications of different classes of anti-HT were unexplored in South India. Our aim is to compare PFT among hypertensive (HT) &healthy controls and also among HT taking various classes of anti-HT. Methods: Case control study. Age- matched healthy controls (n=91) HT cases (n=93) randomly selected. Group I Beta blockers (n= 14), Group II Calcium Channel blockers (n= 18), Group III Angiotensin receptor blockers (n=23), Group IV drug combinations (n= 38).Anthropometry taken, BP recorded, PFT assessed using Easyone Spirometer and data analysed using ANOVA and Student “t” test. Results: Study results show statistically significant reduction in PFT values in all groups of cases and also in females. Out of 93 cases, 49 normal PFT, 7 obstructions, 5 restrictions, 32 mixed airway disease. PFT statistically significantly reduced among various classes of anti –HT, FVC (p=0.026), FEV1 (p=0.000), PEFR (p=0.038). Interpretation & Conclusion: We conclude reduction in PFT among HT taking various common classes of anti-HT and hence recommend periodic evaluation of PFT in all HT patients.